Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study

1/11 Late treatment study

Ceccarelli et al., Frontiers in Medicine, doi:10.3389/fnut.2020.613928 (Peer Reviewed)
Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study

Source PDF Share Tweet

Retrospective 200 severe condition hospitalized patients in Italy, 88 treated with probiotic Sivomixx, showing lower mortality with treatment.

Ceccarelli et al., 1/11/2021, retrospective, Italy, Europe, peer-reviewed, 14 authors.

risk of death, 64.2% lower, RR 0.36, p < 0.001, treatment 10 of 88 (11.4%), control 34 of 112 (30.4%), adjusted per study, odds ratio converted to relative risk.

risk of ICU admission, 15.2% lower, RR 0.85, p = 0.60, treatment 16 of 88 (18.2%), control 24 of 112 (21.4%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 6 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit